Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

BACKGROUND: Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastases that r...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Robert, Liu, Mitchell, Bergman, Alanah, Lam, Sonya, Hsu, Fred, Mou, Benjamin, Berrang, Tanya, Mestrovic, Ante, Chng, Nick, Hyde, Derek, Matthews, Quinn, Lund, Chad, Glick, Daniel, Pai, Howard, Basran, Parminder, Carolan, Hannah, Valev, Boris, Lefresene, Shilo, Tyldesley, Scott, Schellenberg, Devin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172706/
https://www.ncbi.nlm.nih.gov/pubmed/30286739
http://dx.doi.org/10.1186/s12885-018-4859-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172706/
https://www.ncbi.nlm.nih.gov/pubmed/30286739
http://dx.doi.org/10.1186/s12885-018-4859-7

Ejemplares similares